ATNX Athenex Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATNX

Price (delayed)

$3.56

Market cap

$389.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.59

Enterprise value

$454.13M

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment ...

Highlights
ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter
The quick ratio has contracted by 36% from the previous quarter but it has grown by 8% YoY
ATNX's net income is down by 25% year-on-year but it is up by 4.1% since the previous quarter
Athenex's debt has increased by 49% YoY
The gross profit has declined by 25% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.athenex.com
Peers: ONTX OPK

Key stats

What are the main financial stats of ATNX
Market
Shares outstanding
109.31M
Market cap
$389.14M
Enterprise value
$454.13M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.8
Price to sales (P/S)
3.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
Earnings
Revenue
$120.23M
EBIT
-$136.83M
EBITDA
-$131.99M
Free cash flow
-$149.41M
Per share
EPS
-$1.59
Free cash flow per share
-$1.45
Book value per share
$1.98
Revenue per share
$1.16
TBVPS
$2.58
Balance sheet
Total assets
$408.96M
Total liabilities
$239.08M
Debt
$158.43M
Equity
$185.2M
Working capital
$150.17M
Liquidity
Debt to equity
0.86
Current ratio
3.39
Quick ratio
2.68
Net debt/EBITDA
-0.49
Margins
EBITDA margin
-109.8%
Gross margin
34.4%
Net margin
-121.1%
Operating margin
-113.5%
Efficiency
Return on assets
-37.5%
Return on equity
-77.8%
Return on invested capital
-44.5%
Return on capital employed
-39.5%
Return on sales
-113.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATNX stock price

How has the Athenex stock price performed over time
Intraday
5.01%
1 week
2.01%
1 month
9.2%
1 year
-72.74%
YTD
-67.81%
QTD
-22.94%

Financial performance

How have Athenex's revenue and profit performed over time
Revenue
$120.23M
Gross profit
$41.39M
Operating income
-$136.48M
Net income
-$145.62M
Gross margin
34.4%
Net margin
-121.1%
The operating margin has dropped by 55% year-on-year and by 22% since the previous quarter
Athenex's net margin has decreased by 47% YoY and by 10% from the previous quarter
The operating income has contracted by 33% YoY and by 6% from the previous quarter
The gross profit has declined by 25% year-on-year and by 11% since the previous quarter

Growth

What is Athenex's growth rate over time

Valuation

What is Athenex stock price valuation
P/E
N/A
P/B
1.8
P/S
3.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.78
The EPS has grown by 10% from the previous quarter but it has contracted by 10% YoY
The P/B is 72% lower than the 5-year quarterly average of 6.5 and 51% lower than the last 4 quarters average of 3.7
ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter
The stock's P/S is 77% below its 5-year quarterly average of 13.2 and 39% below its last 4 quarters average of 5.0
The revenue has decreased by 15% YoY and by 13% from the previous quarter

Efficiency

How efficient is Athenex business performance
The ROS has plunged by 50% YoY and by 16% from the previous quarter
ATNX's return on invested capital is up by 38% year-on-year and by 7% since the previous quarter
ATNX's ROA is up by 11% QoQ and by 3.8% YoY
Athenex's return on equity has increased by 10% QoQ but it has decreased by 8% YoY

Dividends

What is ATNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATNX.

Financial health

How did Athenex financials performed over time
The total assets is 71% more than the total liabilities
The total liabilities is up by 39% year-on-year and by 16% since the previous quarter
The total assets has increased by 37% YoY and by 17% from the previous quarter
Athenex's debt is 14% less than its equity
Athenex's debt has increased by 49% YoY
ATNX's equity is up by 33% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.